Literature DB >> 25755616

Treatment algorithms for managing hepatocellular carcinoma.

Vivek A Saraswat1, Gaurav Pandey1, Sachin Shetty1.   

Abstract

Early diagnosis and aggressive therapy improves outcome in hepatocellular carcinoma (HCC). Several potentially curative as well as palliative treatment options are available for patients. The choice of therapy is influenced by factors such as extent of tumor and severity of underlying liver dysfunction as well as availability of resources and of expertise. A systematic, algorithmic approach would ensure optimal therapy for each patient and is likely to improve outcomes. Even after receiving therapy for HCC, patients remain at risk for recurrent HCC as well as progression of underlying cirrhosis. Proper assessment and monitoring is needed for the underlying liver disease, which may progress to liver failure and have a major impact on long-term survival. Comprehensive care for patients with cirrhosis includes interventions such as antiviral therapy for HBV and HCV, abstention from alcohol, management of fatty liver disease, endoscopic surveillance and treatment for complications of portal hypertension and, if indicated, immunization against HAV and HBV. An algorithmic approach is useful for choosing the most appropriate treatment option for the individual patient from among the various options that are available. The general consensus is that the BCLC system should be preferred for staging HCC as it is useful in predicting outcomes and planning treatment. The BCLC system classifies patients with HCC into five categories: very early, early, intermediate, advanced, and terminal. It incorporates data on tumor status (number and size of nodules, vascular invasion, extra-hepatic spread), liver function (CTP status, presence of portal hypertension) and overall health status (constitutional symptoms, cancer symptoms, performance status). Treatment allocation according to sub-class of patients is a merit of the BCLC system; a few limitations have been noted, particularly with respect to patients with BCLC stage B and C disease. The treatment algorithm as per BCLC system is summarized in this review.

Entities:  

Keywords:  AJCC–UICC, American Joint Committee on Cancer and Union for International Cancer Control; ALT, alanine aminotransferase; BCLC; BCLC, Barcelona Clinic Liver Cancer; CEUS, contrast-enhanced ultrasound; CLIP, Cancer of the Liver Italian Program; CTP, Child–Turcotte–Pugh criteria; CUPI, Chinese University Prognostic Index; EASL, European expert panel; EBRT, external beam radiotherapy; HCC, hepatocellular carcinoma; JIS, Japanese integrated system; LT, liver transplantation; MAA, macro-aggregate albumin; MCT, microwave coagulation therapy; MWA, microwave ablation; NCCN, National Comprehensive Cancer Network; PAI, percutaneous acetic acid injection; PEI, percutaneous ethanol injection; PLT, primary LT; RBV, ribavirin; RECIST, response evaluation criteria in solid tumors; RFA, radiofrequency ablation; SIRT, Selective Internal Radiation Treatment; SLT, salvage liver transplant; TACE, trans-catheter arterial chemo-embolization; TACE-DEB, TACE with drug eluting beads; TAE, transarterial embolization; TAI, trans-catheter hepatic arterial infusion; TARE, transarterial radio-embolization; TNM, Tumor-Node-Metastasis; WHO, World Health Organization; bm-JIS, biomarker JIS; liver cancer; staging; treatment algorithm

Year:  2014        PMID: 25755616      PMCID: PMC4284287          DOI: 10.1016/j.jceh.2014.05.004

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  45 in total

1.  Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence.

Authors:  Wei Yang; Min Hua Chen; Shan Shan Yin; Kun Yan; Wen Gao; Yan Bin Wang; Ling Huo; Xiao Peng Zhang; Bao Cai Xing
Journal:  AJR Am J Roentgenol       Date:  2006-05       Impact factor: 3.959

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Authors:  S Chevret; J C Trinchet; D Mathieu; A A Rached; M Beaugrand; C Chastang
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

5.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?

Authors:  Ju Hyun Shim; Joong-Won Park; Joon-Il Choi; Hyun-Beom Kim; Woo Jin Lee; Chang-Min Kim
Journal:  J Vasc Interv Radiol       Date:  2008-12-12       Impact factor: 3.464

9.  First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis.

Authors:  G Vennarecci; G M Ettorre; M Antonini; R Santoro; M Maritti; G Tacconi; D Spoletini; L Tessitore; L Perracchio; G Visco; C Puoti; E Santoro
Journal:  Transplant Proc       Date:  2007 Jul-Aug       Impact factor: 1.066

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  31 in total

Review 1.  Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma.

Authors:  Jason Wachsmann; Fangyu Peng
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection.

Authors:  Bingnan Zhang; Richard S Finn
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

3.  Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration.

Authors:  Shuyuan Zhang; Liem H Nguyen; Kejin Zhou; Ho-Chou Tu; Alfica Sehgal; Ibrahim Nassour; Lin Li; Purva Gopal; Joshua Goodman; Amit G Singal; Adam Yopp; Yu Zhang; Daniel J Siegwart; Hao Zhu
Journal:  Gastroenterology       Date:  2017-12-21       Impact factor: 22.682

4.  Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma?

Authors:  Berardino De Bari; Mahmut Ozsahin; Pierre Bize; Tarek Boussaha; Gaël Deplanque; Dorothea Wagner; Jean Bourhis; Alban Denys
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 5.  Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry.

Authors:  Aaron K T Tong; Yung Hsiang Kao; Chow Wei Too; Kenneth F W Chin; David C E Ng; Pierce K H Chow
Journal:  Br J Radiol       Date:  2016-03-24       Impact factor: 3.039

6.  Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.

Authors:  Fengyong Liu; Zhiqiang Meng; Guoliang Shao; Jianhua Wang; Zhijun Wang; Jijin Yang; Christina S M Yip; Dongfeng He
Journal:  Mol Biol Rep       Date:  2016-12-15       Impact factor: 2.316

Review 7.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

8.  A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.

Authors:  Qiaohua Zhu; Meihua Luo; Chengyu Zhou; Zhiwei Zhou; Zhixu He; Xinfa Yu; Shufeng Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

9.  Antitumor effects of combining tumor radiation with the antivascular action of ultrasound stimulated microbubbles.

Authors:  Yanlei Ji; Zhen Han; Limei Shao; Yuehuan Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 10.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.